An observational study in Chronic Thromboembolic Pulmonary Hypertension, Takayasu Arteritis and Takayasu Arteritis With Pulmonary Artery Involvement, sponsored by Chinese Pulmonary Vascular Disease Research Group. Recruiting at 2 sites in China. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-12.
Sponsored by Chinese Pulmonary Vascular Disease Research Group · Observational
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 26 studies in Takayasu Arteritis with a site in China — 15 open to participants now, 16 under way, 2 of them phase 3. Takayasu Arteritis · China.
Among the 26 studies in Takayasu Arteritis with a site in China, this one is the 3rd largest by planned enrollment of the 11 observational ones that give a count, is the only one that started in 2018, is one of 11 observational ones, reaches primary completion later than 15 of the 15 other live ones, and was the 10th registered.
79 studies on the registry are indexed under Takayasu Arteritis; 33 are open to participants now.
Browse Takayasu Arteritis studies →15 of the 26 studies in Takayasu Arteritis with a site in China are open now. Recruiting first, the newest first:
Shanghai Zhongshan Hospital · Sites in China
Ages 18–65
Xuanwu Hospital, Beijing · Sites in China
Ages 18–65
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
Chinese SLE Treatment And Research Group · Sites in China
Ages 18–65
Shanghai Zhongshan Hospital · Sites in China
Ages 18–65
A study can be open while its sites in China have not opened yet or have stopped. Only those recruiting at a site in China →
Of the 25 Takayasu Arteritis studies recruiting now, 13 (52%) set no upper age limit and 10 (40%) stop at 75 or younger; 10 take children under 18; 6 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
26 studies; the count open now beside each. This study's row is marked.
First in 2011; this study’s year is marked. 1 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 2,000 is above the median of 262 across 42 observational studies indexed under Takayasu Arteritis.
Median enrollment 76 across the 15 interventional studies, 1,000 across the 11 observational. Of the 5 that completed or were terminated, 0 (0%) have results posted.
This tab as a report to print or save as PDF → With an account.
1 of 26 have an industry lead sponsor. The 10 most frequent:
Chinese Pulmonary Vascular Disease Research Group is the lead sponsor of 17 studies on the registry; 11 are open to participants now.
Chinese Pulmonary Vascular Disease Research Group has 2 studies filed under Takayasu Arteritis — fewer than ten, so there is no comparison to draw.
2 of the studies in Takayasu Arteritis with a site in China that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT03372980Beijing Institute of Heart, Lung and Blood Vessel DiseasesA Registry Study on Biomarkers of Takayasu's Arteritis (ARSBTA) | 2026-12 |
| NCT07184814China-Japan Friendship HospitalClinical Features and Prognosis of Takayasu's Arteritis With Pulmonary Arteries Involvement | 2026-12-31 |
Add all 2 to your calendar (.ics) → With an account.
Among the 26 studies in Takayasu Arteritis with a site in China, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
Balloon pulmonary angioplasty (BPA) is a potential treatment for patients with pulmonary artery stenosis, including non-operable patients with chronic thromboembolic pulmonary hypertension (CTEPH), takayasu arteritis and fibrosis mediastinitis.
The aim of this study was to evaluate the safety and efficacy of BPA in CTEPH and patients not amenable to pulmonary endarterectomy(PEA) or suffered from persistent CTEPH after PEA, , takayasu arteritis and fibrosis mediastinitis.
This study is a prospective, multi-center, long-term observational project to study the safety and efficacy of BPA. Clinical evaluation, including: functional capacity, 6-minutes walking test, biomarkers, cardiopulmonary exercise test, electrocardiography, echocardiography, haemodynamics, pulmonary angiography and lung scintigraphy was performed before the initiation therapy of BPA, and 3-12 months after last session of BPA.
we also aim to evaluate the value of FAPI in predicting the efficacy and the prognosis of patients with CTEPH who received BPA.
Chronic thromboembolic pulmonary hypertension patients admitted in hospital.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Balloon pulmonary angioplasty is an interventional technique where a balloon catheter is used to recanalize affected segments of pulmonary arteries identified during angiography.
Also known as: BPA
Incidence of Treatment-Emergent Adverse Events of BPA procedure.
Surveillance of complications including: vessel injury, desaturation, cough, mild hemoptysis (\<50ml), severe hemoptysis (\>50ml), reperfusion pulmonary injury, death.
Time frame: From initiation of BPA to 3-12 months after last session
Change of Pulmonary artery pressure in mmHg caused by series of BPA.
Pulmonary artery pressure in mmHg is obtained by right cardiac catheterization.
Time frame: From initiation of BPA to 3-12 months after last session
Change of Pulmonary vascular resistance (PVR) in Wood U caused by series of BPA.
Pulmonary vascular resistance (PVR) in Wood U is obtained by right cardiac catheterization.
Time frame: From initiation of BPA to 3-12 months after last session
Change of cardiac index (CI) in L/m^2 caused by series of BPA.
Cardiac index (CI) in L/m\^2 is obtained by right cardiac catheterization.
Time frame: From initiation of BPA to 3-12 months after last session
Change of World Health Organization (WHO) functional capacity classification caused by series of BPA.
World Health Organization is obtained from electronic medical records.
Time frame: From initiation of BPA to 3-12 months after last session
Change of six minutes walk distance in meter caused by series of BPA.
World Health Organization is obtained from electronic medical records.
Time frame: From initiation of BPA to 3-12 months after last session
Change of N-terminal B-type natriuretic peptide in pg/ml caused by series of BPA.
World Health Organization is obtained from electronic medical records.
Time frame: From initiation of BPA to 3-12 months after last session
Change of Peak VO2/kg in ml/min/kg caused by series of BPA.
Peak VO2/kg in ml/min/kg is obtained by cardiopulmonary exercise test.
Time frame: From initiation of BPA to 3-12 months after last session
Change of diffusing capacity for carbon monoxide caused by series of BPA.
diffusing capacity for carbon monoxide in % is obtained from pulmonary function test
Time frame: From initiation of BPA to 3-12 months after last session
Change of fibroblast activation protein inhibitor expression after BPA
Change of fibroblast activation protein inhibitor expression after BPA
Time frame: From initiation of BPA to 3-12 months after last session
Started May 2018 (actual). Primary completion is estimated for May 2065, 564 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Chinese Pulmonary Vascular Disease Research Group